Vir Biotechnology Stock Forecast

Stock Price Forecast

According to 10 analysts polled by S&P Global, Vir Biotechnology stock has a consensus rating of "Strong Buy" and an average price target of $20.67. The average 1-year stock price forecast is 138.96% higher than the current stock price, while the lowest is $16 (+84.97%) and the highest is $30 (+246.82%).

Price Target: $20.67 (+138.96%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$16	$20.67	$20	$30
Change	+84.97%	+138.96%	+131.21%	+246.82%

Analyst Ratings

The average analyst rating for Vir Biotechnology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	6	7	7	7	7	7
Buy	4	3	3	3	3	3
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	10	10	10	10	10	10

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Patrick Trucchio H.C. Wainwright	H.C. Wainwright	Buy Reiterates $20	Buy	Reiterates	$20	+131.21%	Jun 4, 2026
Etzer Darout Barclays	Barclays	Buy Maintains $30	Buy	Maintains	$30	+246.82%	Jun 1, 2026
Alec Stranahan Bank of America Securities	Bank of America Securities	Buy Maintains $16	Buy	Maintains	$16	+84.97%	May 29, 2026
Roanna Ruiz Leerink Partners	Leerink Partners	Buy Reiterates n/a	Buy	Reiterates	n/a	n/a	May 27, 2026
Michael Ulz Morgan Stanley	Morgan Stanley	Buy Maintains $24 → $23	Buy	Maintains	$24 → $23	+165.90%	May 8, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

249.42M

from 68.56M

263.82%

from 68.56M

Revenue Next Year

112.90M

from 249.42M

-54.74%

from 249.42M

EPS This Year

-1.37

from -3.16

EPS Next Year

-2.32

from -1.37

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	1.10B	1.62B	86.18M	74.21M	68.56M	249.42M
Revenue Growth	1,334.39%	47.50%	-94.67%	-13.90%	-7.61%	263.82%
Gross Profit	581.54M	994.83M	-486.65M	-418.59M	-375.95M	226.48M
Gross Margin	53.09%	61.57%	-564.69%	-564.10%	-548.38%	90.80%
Operating Income	420.75M	833.07M	-661.09M	-537.62M	-468.02M	-265.08M
Net Income	528.58M	515.84M	-615.06M	-521.96M	-437.99M	-237.77M
EPS	-	-	-	-	-3.16	-1.37
Free Cash Flow	-246.55M	1.47B	-597.12M	-372.22M	-174.44M	-233.10M
No. Analysts	-	-	-	-	-	5

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	320.9M
Avg	249.4M
Low	192.0M

Revenue Growth

Revenue Growth	2026	2027	2028
High	368.1%
Avg	263.8%
Low	180.1%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-1.37
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-